<DOC>
	<DOC>NCT00555620</DOC>
	<brief_summary>The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer</brief_summary>
	<brief_title>Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>confirmed diagnosis of stomach cancer advanced stomach cancer of stage IV adequate blood chemistry, blood counts and kidney function willing to participate to study requirements and sign an informed consent document prior chemotherapy for the stomach cancer in its advanced stage excessive toxicities related to prior therapies pregnant or breastfeeding patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>